Hepatitis B Surface Antibody (HBsAb)

The Quantitative detection Hepatitis B virus Surface IgG antibody (HBSAb) in human sera using the FDA approved Abbott ARCHITECT AUSAB-DIL test two-step chemiluminescent immunoassay.

In the first step, sample, assay diluent, and recombinant Hepatitis B surface Antigen (rHBsAg) coated paramagnetic microparticles are combined. Anti-HBs present in the sample binds to the rHBsAg coated microparticles. In the second step, rHBsAg acridinium-labeled conjugate is added, which binds to IgG anti-HBs. Then pre-trigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units (RLUs).

A direct relationship exists between the amount of anti-HBs in the sample and the RLUs. The concentration of anti-HBs in the sample is determined using an active ARCHITECT AUSAB calibration curve. Results are reported as mIU/mL.

For Batteries containing HBSAb see:

Hepatitis B Antibodies (HBcAB, HBsAB) [HBAB], Quantitative detection of Hepatitis B virus Surface IgG antibody (HBSAb) and Hepatitis B virus Core IgG and IgM antibodies (HBCAb)

Hepatitis B Battery [HBB], Quantitative detection of Hepatitis B virus Surface IgG antibody (HBSAb), Qualitative detection of Hepatitis B virus Surface Antigen (HBSAg) and Qualitative detection of Hepatitis B virus Core IgG and IgM antibodies (HBCAb)

Hepatitis B Surface Antigen & Antibody (HBsAg, HBsAb) [HBSS], Quantitative detection of Hepatitis B virus Surface IgG antibody (HBSAb) and Qualitative detection of Hepatitis B virus Surface Antigen (HBSAg)